M&A Deal Summary |
|
|---|---|
| Date | 2025-06-03 |
| Target | Agenus - Biologics CMC Facilities |
| Sector | Life Science |
| Buyer(s) | Zydus Lifesciences |
| Sellers(s) | Agenus |
| Deal Type | Divestiture |
| Deal Value | 125M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1952 |
| Sector | Life Science |
| Employees | 27,917 |
| Revenue | 225.7B INR (2025) |
Zydus Lifesciences is a pharmaceutical company that discovers, develops,manufactures and markets a broad range of healthcare therapies. Zydus Lifesciences was formed in 1952 and is based in Ahmedabad, Gujarat.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-30 |
Zypitamag
United States Zypitamag is an HMG-CoA reductase inhibitor indicated for adult patients with primary hyperlipidemia or mixed dyslipidemia as adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) |
Sell | $7M |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 389 |
| Revenue | 103M USD (2024) |
Agenus is a biotechnology company developing treatments for cancers and infectious diseases. Agenus was incorporated in 1994 and is based in Lexington, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-23 |
PhosImmune
Charlottesville, Virginia, United States PhosImmune, Inc. is a developer of therapeutic cancer vaccines. |
Buy | - |
